New York, NY -- (SBWIRE) -- 12/18/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: CombiMatrix Corporation (NASDAQ:CBMX), Rentech, Inc (NASDAQ:RTK), Orexigen Therapeutics, Inc (NASDAQ:OREX), Dynavax Technologies Corporation (NASDAQ:DVAX)
CombiMatrix Corporation (NASDAQ:CBMX) showed a volume of 2.72 million shares by the end of last trade whereas the average volume of the stock remained 1.17 million shares. The stock opened the session at $2.50 but then moved to $2.30. At that price, the stock showed a negative performance of -19.30%. CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. located in Irvine, California. The Company operates as a diagnostics reference laboratory, providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of pre-and postnatal development disorders and hematology/oncology genomics.
Will CBMX Get Buyers Even After The Recent Rally? Find Out Here
Rentech, Inc (NASDAQ:RTK) opened the session at $1.68 and closed the session at 1.65. The stock showed a negative performance of -2.94% in previous trading session. Traded with volume of 2.71 million shares in the prior session and the average volume of the stock remained 2.11 million shares. Rentech, Inc. (Rentech) is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States. It is developing energy projects to produce certified synthetic fuels and electric power from carbon-containing materials, such as biomass, waste and fossil resources.
Has RTK Found The Bottom And Ready To Gain Momentum? Find Out Here
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $5.48 and closed the session at $5.38. The stock showed a negative performance of -2.36% in previous trading session. Traded with volume of 2.67 million shares in the prior session and the average volume of the stock remained 2.75 million shares. The beta of the stock remained 2.14. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Why Should Investors Buy OREX After the Recent Fall? Just Go Here and Find Out
Dynavax Technologies Corporation (NASDAQ:DVAX) the stock decreased -1.68% and finished the session at $1.76. Traded with volume of 2.65 million shares in the prior session and the average volume of the stock remained 5.08 million shares. The beta of the stock remained -2.75. Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company’s pipeline of product candidates includes HEPLISAV,
Will DVAX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)